Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Bystrinsky GOK intends to double its production capacity

7/5/23 GMKN

Investments in Eastern Transit Terminal project will be about ₽18 billion

7/5/23 FESH

Fesco plans to increase the capacity of VMTP to 1.2 mln. TEU

7/5/23 FESH

Shareholders of Abrau-Durso approved dividends for 3 months 2023

7/5/23 ABRD

Yandex launched service for organizing business trips Yandex Travel

7/5/23 YNDX

Ozon entered the Armenian market

7/5/23 OZON

SPB Exchange summarized the results of trading in June

7/5/23 SPBE

Pharmsintez placed an additional issue of 46.3% of capital

7/4/23 LIFE

Moscow Exchange summarized the results of trading in June

7/4/23 MOEX

Samokat opened the possibility of ordering goods through the site

7/4/23 SBER